Prenetics Global Limited

What they do

The company operates through subsidiaries in Hong Kong and other non-mainland China jurisdictions, providing pharmaceutical and diagnostic products and services. Its two mainland China subsidiaries are dormant with no active business, material assets, or revenue. The company is not a mainland Chinese operating company; it holds equity interests in its subsidiaries from the Cayman Islands parent.

Revenue drivers

• Hong Kong operations — Principal revenue-generating subsidiary location; all revenue for 2023-2025 was generated from businesses outside mainland China.
• Other non-mainland China jurisdictions — Subsidiaries in jurisdictions outside mainland China also contribute revenue.
• Dormant mainland China entities — No revenue contribution; not a material driver.

Recent performance

For fiscal year ended December 31, 2025, the company generated all revenue from businesses outside mainland China. No specific revenue or profit figures were provided in the excerpt. The company filed an amended 20-F to address SEC comments on non-IFRS measures, operating metrics, and subscription model. As of December 31, 2025, there were 16,874,089 ordinary shares issued and outstanding: 15,293,117 Class A and 1,580,972 Class B, plus 17,352,363 warrants.

Strategy

The company is revising disclosures on holding company structure and cash transfers within the group, indicating a focus on transparency. It is also updating descriptions of operating metrics and subscription model, suggesting these are key to its business approach. The company is an emerging growth company and has elected not to use the extended transition period for new accounting standards.

Risks

• Holding company structure risk — Investors purchase equity in the Cayman Islands parent, not the operating subsidiaries, which may limit direct recourse.
• Concentration in non-mainland China operations — All revenue is generated from outside mainland China, exposing the company to regional economic and regulatory conditions.
• Regulatory permissions risk — Operations may require permissions from PRC authorities, and the company's disclosure on this is incomplete in the excerpt.
• SEC scrutiny on disclosures — The 20-F/A was filed in response to SEC comments, indicating potential compliance and reporting challenges.

Outlook

Management has not provided forward-looking statements in the excerpt. The amendment focuses on clarifying legal and financial disclosures. The company continues to operate with subsidiaries outside mainland China and is addressing regulatory feedback.